Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives

被引：1
|
作者：
Irfan, Hamza [1 ,3 ]
Ahmed, Aliza [2 ]
机构：
[1] Shaikh Khalifa Bin Zayed Al Nahyan Med & Dent Coll, Dept Med, Lahore, Pakistan
[2] Jinnah Sindh Med Univ, Dept Med, Karachi, Pakistan
[3] Shaikh Khalifa Bin Zayed Al Nahyan Med & Dent Coll, G855 XRM,Sheikh Zayed Med Complex,Block D, Lahore, Pakistan
来源：
HEALTH SCIENCE REPORTS | 2024年 / 7卷 / 06期
关键词：
DOUBLE-BLIND; IMMUNOGENICITY; SAFETY;
D O I：
10.1002/hsr2.2183
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页数：4
相关论文
共 3 条
  • [1] Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection
    Ly, Hinh
    VIRULENCE, 2024, 15 (01)
  • [2] West Nile-like virus, pneumococcal vaccine, FDA approval for Synercid, influenza a diagnostic test
    不详
    INFECTIONS IN MEDICINE, 1999, 16 (11) : 695 - 696
  • [3] The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
    Weber, Whitney C.
    Streblow, Zachary J.
    Kreklywich, Craig N.
    Denton, Michael
    Sulgey, Gauthami
    Streblow, Magdalene M.
    Marcano, Dorca
    Flores, Paola N.
    Rodriguez-Santiago, Rachel M.
    Alvarado, Luisa I.
    Rivera-Amill, Vanessa
    Messer, William B.
    Hochreiter, Romana
    Kosulin, Karin
    Dubischar, Katrin
    Buerger, Vera
    Streblow, Daniel N.
    VACCINES, 2024, 12 (08)
1